These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9404486)

  • 21. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
    Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
    Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
    Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
    Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
    Lichtman MA
    Oncologist; 2008 Jun; 13(6):645-54. PubMed ID: 18586919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blastic phase of chronic myelogenous leukemia.
    Morris EL; Dutcher JP
    Clin Adv Hematol Oncol; 2005 Jul; 3(7):547-52. PubMed ID: 16167037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studying the pathogenesis of BCR-ABL+ leukemia in mice.
    Van Etten RA
    Oncogene; 2002 Dec; 21(56):8643-51. PubMed ID: 12476310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy.
    Emanuel PD; Shannon KM; Castleberry RP
    Mol Med Today; 1996 Nov; 2(11):468-75. PubMed ID: 8947912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.
    Bastie JN; Aucagne R; Droin N; Solary E; Delva L
    Cell Mol Life Sci; 2012 Sep; 69(17):2853-61. PubMed ID: 22415325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Acute transformation of chronic myelomonocytic leukemia with t(1;3) (p36;q21) abnormality].
    Onishi Y; Nakamichi T; Maeda Y; Chinzei T; Nakagawa T; Saigo K
    Rinsho Ketsueki; 1998 Jul; 39(7):519-25. PubMed ID: 9750460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic myelomonocytic leukemia with p190 BCR-ABL rearrangement mimicking advanced liver disease at presentation.
    Alagiozian-Angelova V; Kadkol S; Lindgren V; Peace D; Gaitonde S
    Acta Oncol; 2007; 46(4):554-6. PubMed ID: 17497325
    [No Abstract]   [Full Text] [Related]  

  • 31. Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker.
    Sun X; Li J; Chen J; Li D; Chen L; Xu W; Yang Y; Wu Y; Jiang P; Xie W
    Ann Hematol; 2009 Jan; 88(1):29-36. PubMed ID: 18696070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in targeted therapy for chronic myeloid leukemia.
    Yee KW; Keating A
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):295-310. PubMed ID: 12820774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?
    Roumier C; Daudignon A; Soenen V; Dupriez B; Wetterwald M; Lai JL; Cosson A; Fenaux P; Preudhomme C
    Haematologica; 1999 Dec; 84(12):1075-80. PubMed ID: 10586207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.
    Gratias EJ; Liu YL; Meleth S; Castleberry RP; Emanuel PD
    Pediatr Blood Cancer; 2005 Feb; 44(2):142-6. PubMed ID: 15390271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular mechanism and progress in treatment of juvenile myelomonocytic leukemia (JMML)].
    Koike K; Matsuda K
    Rinsho Ketsueki; 2013 Jun; 54(6):538-44. PubMed ID: 23823092
    [No Abstract]   [Full Text] [Related]  

  • 37. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Overview].
    Gotoh A
    Rinsho Ketsueki; 2016 Feb; 57(2):117. PubMed ID: 26935628
    [No Abstract]   [Full Text] [Related]  

  • 40. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia.
    Hasegawa D; Manabe A; Kubota T; Kawasaki H; Hirose I; Ohtsuka Y; Tsuruta T; Ebihara Y; Goto Y; Zhao XY; Sakashita K; Koike K; Isomura M; Kojima S; Hoshika A; Tsuji K; Nakahata T
    Br J Haematol; 2005 Mar; 128(6):805-12. PubMed ID: 15755284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.